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Purpose: To evaluate the effect of repeated intravitreal ranibizumab injections for neovascular 
age related macular degeneration (nAMD) on the retinal nerve fiber layer (RNFL) thickness 
using optical coherence tomography.
Design: A prospective observational cohort study of patients with nAMD.
Methods: Thirty eyes of 30 patients with nAMD were selected. All patients received three 
ranibizumab injections and underwent scans using the fast RNFL thickness protocol (Stratus 
optical coherence tomography) before starting the first injection and 1 month after the third 
injection. The RNFL thickness measurements prior to the injections and after the third injection 
were used for the analysis. We also evaluated the effect of the lens status as well as the type of 
choroidal neovascular membrane on RNFL thickness measurements pre- and post-injection. 
Pre- and post-injection average and individual quadrant RNFL thickness were measured and 
statistically analyzed.
Results: The mean (± standard deviation) pre-injection RNFL thickness was 90.8±18. The 
mean (± standard deviation) post-injection RNFL thickness was 91.03±15. The pre- and post-
injection values of the mean RNFL thickness were not statistically significant. Likewise, the 
pre- and post-injection values for RNFL thickness in the different quadrants were not statisti-
cally significant. There was no statistical significance for the lens status or the type of choroidal 
neovascular membrane on the RNFL thickness.
Conclusion: Repeated ranibizumab injections in nAMD appear to have no harmful effect on 
the RNFL thickness in the short term, in spite of the proven neurotrophic effect of vascular 
endothelial growth factor. Nevertheless, the safety profile of ranibizumab injections in nAMD 
needs to be further evaluated in a large multicenter trial with special emphasis on the long-term 
effects on the retina and optic nerve.
Keywords: optical coherence tomography, anti-VEGF, intraocular pressure, ranibizumab, 
retinal nerve fiber layer
Introduction
Neovascular age related macular degeneration (nAMD), characterized by new forma-
tion of choroidal vessels into the sub-retinal space,1 is responsible for nearly 90% of 
severe vision loss among elderly people in the developed world.2 Vascular endothelial 
growth factor (VEGF)-A is a key contributory factor in the pathophysiology underly-
ing nAMD.3 Several studies have shown that the rise in ocular VEGF levels is linked 
to the initiation of neovascularization, which is the first step in the pathogenesis of 
nAMD in both humans3 and animals.4,5
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Ranibizumab (anti-VEGF), a recombinant humanized 
monoclonal antibody antigen-binding fragment, has been 
reported to neutralize all known active forms of VEGF-A 
and to block vessel permeability and angiogenesis and hence 
prevent vision loss and improve visual acuity in patients with 
nAMD.6
Major trials have proven the beneficial effect of ranibi-
zumab (anti-VEGF) injections in nAMD.7,8 However, VEGF 
has a potential role in the maintenance and survival of retinal 
neural cells, since it was shown to increase vascular perme-
ability and vascular endothelial cell proliferation, as well as 
promote cell survival.9 Being expressed by astrocytes in the 
retinal ganglion cell layer and by cells of the inner nuclear 
layer, Muller cells, and the retinal pigment epithelium, 
VEGF-A imparts a neuroprotective role on the retina and 
optic nerve. In addition, it plays a central role in the trophic 
maintenance of the choriocapillaris and in protecting retinal 
neurons from apoptosis.9 Repeated ranibizumab injections 
might therefore induce a detrimental effect on the retinal 
nerve fiber layer (RNFL) thickness. The purpose of this study 
was to evaluate the effect of repeated intravitreal ranibizumab 
injections for nAMD on the RNFL thickness using Stratus 
optical coherence tomography (OCT).
Materials and methods
This is a prospective observational cohort study of patients 
with nAMD. The study was conducted in accordance with the 
Declaration of Helsinki recommendations. Informed consent 
was obtained from all participants. Thirty white Caucasian 
patients (30 eyes) diagnosed with nAMD participated in the 
study that was carried out in a tertiary referral center in the 
UK. All patients underwent full ophthalmological exami-
nations including slit lamp examination and fundus biomi-
croscopy. Fundus fluorescein angiography was performed 
to identify the type of choroidal neovascular membrane 
(CNV). Patients who showed evidence of glaucoma, ocular 
hypertension, other retinal pathology or systemic diseases, 
such as diabetes, were excluded. All patients received ini-
tially three monthly intravitreal ranibizumab injections and 
then were reviewed on a monthly basis and given further 
injections if needed based on the OCT-guided PrONTO trial 
(Prospective OCT Imaging of Patients with nAMD Treated 
With Intraocular Lucentis). Intraocular pressure (IOP) was 
checked immediately after each injection and patients were 
given anti-glaucoma drops, as required.
OCT scanning
Cross-sectional imaging of the peripapillary area was per-
formed with the Stratus OCT (version 3, Carl Zeiss Meditec 
AG, Jena, Germany). RNFL thickness was assessed by the 
fast RNFL program, a commonly used protocol, which 
compares results to a reference normative database. The 
protocol generates A-scans along a 360-degree circular 
path located 1.74 mm from the center of the optic disc, 
producing a total of three separate scans during each test. 
It generates RNFL thickness measurement for each of the 
twelve 30-degree sectors, computing an average for each of 
the four quadrants (superior, inferior, nasal, temporal) and 
an overall average.
Internal fixation was used during scanning, and all eyes 
had circular scans of 3.4 mm diameter centered around the 
optic disc. The patients underwent scans prior to the first 
injection and 1 month after the third injection at the same 
time as their macular scans for nAMD were performed. All 
the scans were performed by the same investigator. Pre- and 
post-injection scans were analyzed and scans with signal 
strength (SS) of 7 and above were considered acceptable 
except in cases of cataract causing degraded image quality 
on OCT, SS values of 6 and above were considered accept-
able. Pre- and post-injection average and individual quadrant 
RNFL thickness measurements at different quadrants were 
measured and statistically analyzed using SPSS10. We 
also evaluated the effect of the lens status as well as the 
type of CNV on RNFL thickness measurements. Statistical 
comparisons were done using the paired Student’s t-test. A 
P-value of less than or equal to 0.05 was considered statisti-
cally significant.
Results
Thirty participants (30 eyes) were included in the analysis: 
24 (80%) women and six (20%) men, with age range between 
59 and 93 years (mean 77.6). 27 eyes were phakic and three 
were pseudophakic. All patients were diagnosed with CNV 
(ten classic and 19 occult) except one who was diagnosed 
with retinal angiomatous proliferation. The mean (± standard 
deviation) pre-injection RNFL thickness was 90.8±18. The 
post-injection mean (± standard deviation) RNFL thickness 
was 91.03±15. Pre- and post-injection average and quadrant 
RNFL thickness values are shown in Figure 1. Statistical 
analyses of average and quadrant RNFL thickness differences 
are summarized in Table 1. The pre- and post-injection values 
of the mean RNFL thickness were not statistically signifi-
cant. Likewise, the pre- and post-injection values for RNFL 
thickness in the different quadrants were not statistically 
significant. Differential analysis of the changes in the RNFL 
thickness has been performed and showed no statistically 
significant changes due to variation in the type of the CNV 
membrane (classic, occult), as shown in Table 2.
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Post-injection high IOP was recorded in six patients, 
but only two had a reading above 30 mmHg controlled with 
topical anti-glaucoma medications. IOP changes after each 
injection compared with the initial reading were not statisti-
cally significant (data not shown).
Discussion
Endogenous VEGF has neurotrophic and neuroprotec-
tive effects on neuronal cells with an important role in the 
maintenance and function of the adult retina and neural 
cells.10 Suppression of endogenous VEGF by the use of 
intravitreal ranibizumab could potentially have a detrimen-
tal effect on the neuronal cells and hence the rationale for 
assessing the effect of anti-VEGF on the RNFL thickness 
in nAMD patients.
In 2010, Horsley et al evaluated the effect of long-term 
treatment with anti-VEGF agents on the RNFL thickness 
using patients who received more than ten injections and 
found no significant change.11 Our findings are consistent 
with their results, however, in our study, the scope of com-
parison was wider, as further analysis of the changes in the 
RNFL thickness in the different quadrants was adopted and 
showed no statistically significant change in any quadrant. 
An additional unique feature of our study is the fact that we 
have also taken into consideration the effect of lens status 
and the type of membrane (Tables 2 and 3).
In another recent study, Seth et al investigated the poten-
tial change in the optic disc structure due to the combined 
effect of short-term IOP rise, frequent IOP fluctuation, as 
well as the anti-VEGF properties of pegaptanib, and found 
no significant change.12 Moreover, Luke et al showed no 
significant electroretinographic changes on isolated bovine 
retinas after exposure to a concentration of 0.2 mg/mL 
of ranibizumab.13 Similarly, Kim et al reported no severe 
adverse effects on monkeys’ retinas from the combination 
of intravitreal ranibizumab and verteporfin photodynamic 
therapy compared with photodynamic therapy alone.14
In agreement with our study, Sobacı et al found that 
repeated intravitreal injections of ranibizumab or beva-
cizumab does not seem to have adverse effects on RNFL 
thickness in wet AMD patients in contrast to Martinez-de-
la-Casathe et al who concluded that intravitreal ranibizumab 
injections used to treat AMD caused a significant change in 
RNFL thickness after 12 months of follow-up.15,16
The anti-VEGF properties of bevacizumab have also been 
studied in vivo and in vitro and equally no significant difference 
was noted in retinal ganglion cell numbers following either 
single or repeated injections.17 Bevacizumab was also well 
tolerated by ganglion and photoreceptor cells even at concentra-
tions fivefold higher than those used clinically, which further 
supports the safety profile of ranibizumab on the RNFL.18
Intravitreal injections are known to be associated with a 
transient IOP elevation due to volume increase with the injec-
tion of the drug. The IOP usually returns to baseline within 
30–60 minutes post-injection. However, short-term IOP fluctua-
tion has been considered a potential risk factor for the progression 
of glaucomatous damage to the optic nerve head.19 Therefore, 
the cumulative effect of the initial injections could potentially 
damage the RNFL. This effect might be important in cases with 
advanced glaucoma, in which even the slightest change in IOP 
could have a detrimental effect on the optic nerve.
OCT has become an increasingly important tool for 
detecting damage to the RNFL, which may precede the onset 
of detectable visual field defects in patients with glaucoma. 
Papillary RNFL thickness scans have been suggested as the 
preferred metric for measuring the extent of glaucomatous 
damage.20 SS, which is a proxy for the quality of the scan, may 
have a significant impact on the measurements of the RNFL 
on the Stratus OCT. It is claimed that scans with lower SS tend 
to underestimate the thickness of the RNFL. This variability is 
Table 1 Mean and standard deviation of signal strength, average 
rnFl, and quadrant rnFl thickness (in microns)
Mean (± SD)
Variables Pre- 
injection
Post- 
injection 
Difference P-value
ss 7.1±1.62 7.6±1.84 1.7±1.34 0.18
average rnFl 90.8±18.43 91±15.31 7.1±12.85 0.94
superior rnFl 104±28.22 101±23.42 22.7±29.42 0.63
nasal rnFl 72.2±28.90 75.5±25.96 26.4±19.06 0.57
inferior rnFl 112.7±29.91 116.3±27.51 20.7±16.05 0.47
Temporal rnFl 68.6±21.68 65.7±16.93 20±14.46 0.50
Abbreviations: ss, signal strength; sD, standard deviation; rnFl, retinal nerve 
fiber layer.
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Figure 1 Pre- and post-injection quadrant and average rnFl thickness.
Abbreviation: RNFL, retinal nerve fiber layer.
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Table 3 Mean and standard deviation of signal strength, average rnFl, and quadrant rnFl thickness (in microns) in different status 
of the lens
Lens status Variables Pre-injection Post-injection Difference P-value
Phakic ss 7.15±1.9 7.6±1.9 -0.45±2 0.34
average 91.15±2 92.95±15 -1.8±16 0.64
Temporal 68.45±24.5 68.9±17.9 -0.45±28.5 0.94
nasal 74.85±32.6 76±28.6 -1.30±35.4 0.87
superior 102.65±3 104.65±22.8 -2±35.5 0.80
inferior 112.81±28.8 116.6±25 -3.75±28.7 0.57
Cataractous ss 6.86±1.3 7.4±1.8 -0.57±2.4 0.56
average 86.4±15.9 79.9±11.5 6.57±11.6 0.19
Temporal 68.43±16.3 54.7±9.8 13.7±15 0.05
nasal 63.4±21 67.4±15 -4±25.9 0.69
superior 102±11.9 90±14 12.7±12.8 0.39
inferior 106±38.6 102.57±29.5 3.4±21.5 0.69
Pseudophakic ss 7.3±1 8.33±2 -1±3 0.62
average 99±13 104±9.5 -5.3±4 0.15
Temporal 70±18 70±16.8 00±19.97 1.00
nasal 75±18.5 89.7±27.8 -14.3±18.6 0.31
superior 116±41.6 105±43 10.66±16 0.37
inferior 128±8.9 146±18 18±20.8 0.27
Abbreviations: SS, signal strength; RNFL, retinal nerve fiber layer.
Table 2 Mean and standard deviation of signal strength, average rnFl, and quadrant rnFl thickness (in microns) in various types 
of CnV
Mean (± SD)
Variable Pre-injection Post-injection Difference P-value
Occult CnV
ss 7.4±1.7 7.79±1.8 -0.42±2.3 0.44
average rnFl 92.68±13.65 92.16±13.94 0.53±9.56 0.81
superior rnFl 106.6±24.68 108.26±21.12 -1.6±19.7 0.72
nasal rnFl 72.84±26.29 78.58±23.18 -5.74±33.94 0.47
inferior rnFl 118.16±27.12 114.89±29.15 3.26±22 0.53
Temporal rnFl 67.79±17.19 61.37±13.89 6.42±20.13 0.18
Classic CnV
ss 6.5±1.58 7.6±1.8 -1±1.5 0.04
average rnFl 86.5±26.19 87.5±18 -1±23.5 0.89
superior rnFl 96.6±34.8 89.9±22.89 9.7±45.7 0.52
nasal rnFl 73.5±35.25 66.8±30.17 6.7±22 0.37
inferior rnFl 105±34.78 117.8±26.8 -12.7±30.6 0.22
Temporal rnFl 64.6±23.5 73.7±20.65 -9±27.78 0.33
Abbreviations: SS, signal strength; SD, standard deviation; RNFL, retinal nerve fiber layer; CNV, choroidal neovascular membrane.
especially pronounced in patients with advanced optic nerve 
damage, even in scans without error messages. Therefore, 
it is important to obtain scans of similar SS to facilitate the 
longitudinal follow-up of RNFL changes.21 It was concluded 
in another study that SS of at least 7 was required to reduce 
variability, regardless of the RNFL thickness.22 In this study 
scans were repeated until satisfactory level of SS (7 and 
above) was achieved in all cases except in cases with cataract 
(due to the underlying effect of degraded image quality) in 
which SS with values of 6 and above were accepted.
Poor quality scans induced by cataracts might have 
affected the accuracy of RNFL thickness, as measured by 
the Stratus OCT with software version 3.0. It may be pos-
sible that the algorithms in Stratus OCT version 3.0 used to 
identify the RNFL are affected by degraded image quality 
causing imprecision in the measurements.23 OCT has rou-
tinely been used in the assessment of the RNFL thickness 
as a monitoring and screening tool for glaucoma and has 
been shown to have fairly good reproducibility on repeated 
measurements.24–26
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The effect of anti-VEGF on the size and thickness of dif-
ferent types of CNV has been evaluated in other studies.27,28 
Quantitative measurements underlined stable CNV diameters 
for all subtypes but revealed significant reduction of thick-
ness especially for classic CNV components. In occult CNV, 
the thickness of CNV showed a significant reduction only in 
the ranibizumab group. It is not clear whether the peripapil-
lary RNFL thickness would be concurrently affected with 
anti-VEGF injections parallel with the changes in size and 
thickness of the CNV.27,28 Based on the study by Martinez-de-
la-Casa et al the effect of anti-VEGF on the RNFL thickness 
might not be significant shortly after three repeated anti-VEGF 
injections but possibly become evident in the long-term.16 In 
our study there was no significant changes in the RNFL thick-
ness in association with the different types of CNV.
In our study the differences in the measurements pre- 
and post-injection were not statistically significant, possibly 
due to the small number of patients. However, there were 
two outliers in our statistics with up to 40 µm reduction in 
the RNFL thickness after the third injection. Although this 
variance was not statistically significant, the effect could be 
detrimental in cases of end stage glaucoma with advanced 
optic cupping and vulnerable RNFL.
In summary, we evaluated the effect of ranibizumab 
injections on the RNFL thickness and our findings, despite 
originating from a small cohort of patients, suggest that there 
was no significant harmful effect to the RNFL induced by the 
injections. We compared RNFL thickness, both average as well 
as in various peripapillary quadrants, before and after three 
successive monthly ranibizumab injections. Comparing the 
effect of these injections on the RNFL with specific emphasis 
on the different quadrants is a new parameter that has not been 
studied previously and would add strength to this study.
Although our subgroup analysis did focus on the nature of 
the membrane (classic versus occult) and in a similar way on the 
status of the lens the study was not powered for such analyses, 
thus potentially introducing a type II error. Admittedly, our lim-
ited subgroups’ numbers, and relatively short follow-up period 
precludes drawing firm conclusions regarding the value of such 
parameters. Trials with a larger number of patients would be 
recommended to highlight if there was any significance of 
either the lens status or the type of CNV membrane as a vari-
able that might have an implication on the effect of anti-VEGF 
on the RNFL thickness. Similarly, another trial including a 
larger number of glaucoma patients would be recommended 
so that the effect of ranibizumab on the RNFL layer could be 
evaluated in such vulnerable eyes, especially in the context of 
the combined effect of IOP fluctuations and the absence of the 
neuroprotective and neurotrophic effects of VEGF.
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